KZR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KZR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Kezar Life Sciences's Total Assets for the quarter that ended in Dec. 2023 was $221.24 Mil.
During the past 12 months, Kezar Life Sciences's average Total Assets Growth Rate was -13.70% per year. During the past 3 years, the average Total Assets Growth Rate was 20.30% per year. During the past 5 years, the average Total Assets Growth Rate was 22.10% per year.
During the past 8 years, Kezar Life Sciences's highest 3-Year average Total Assets Growth Rate was 88.90%. The lowest was 9.70%. And the median was 26.70%.
Total Assets is connected with ROA %. Kezar Life Sciences's annualized ROA % for the quarter that ended in Dec. 2023 was -54.85%. Total Assets is also linked to Revenue through Asset Turnover. Kezar Life Sciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
The historical data trend for Kezar Life Sciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kezar Life Sciences Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Total Assets | Get a 7-Day Free Trial | 89.51 | 151.84 | 217.93 | 299.57 | 221.24 |
Kezar Life Sciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Assets | Get a 7-Day Free Trial | 299.57 | 284.18 | 263.38 | 249.33 | 221.24 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Kezar Life Sciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (A: Dec. 2023 ) | + | Total Liabilities (A: Dec. 2023 ) |
= | 187.57 | + | 33.665 | |
= | 221.24 |
Kezar Life Sciences's Total Assets for the quarter that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (Q: Dec. 2023 ) | + | Total Liabilities (Q: Dec. 2023 ) |
= | 187.57 | + | 33.665 | |
= | 221.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kezar Life Sciences (NAS:KZR) Total Assets Explanation
Total Assets is connected with ROA %.
Kezar Life Sciences's annualized ROA % for the quarter that ended in Dec. 2023 is
ROA % | = | Net Income (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | -129.04 | / | ( (249.326 | + | 221.235) | / 2 ) | |
= | -129.04 | / | 235.2805 | ||||
= | -54.85 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Kezar Life Sciences's Asset Turnover for the quarter that ended in Dec. 2023 is
Asset Turnover | ||||||
= | Revenue (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | 0 | / | ( (249.326 | + | 221.235) | / 2 ) |
= | 0 | / | 235.2805 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Kezar Life Sciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Morningside Venture Investments Ltd | 10 percent owner | MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459 |
Nicholas Michael Mordwinkin | officer: Chief Business Officer | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Franklin M Berger | director | 1000 MARINA BLVD, STE 200, BRISBANE CA 94005 |
Wallace Courtney | director | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Micki Klearman | director | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Equal Talent Investments Ltd | 10 percent owner | THC MANAGEMENT SERVICES S.A.M. 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVE DE CITRONNIE, MONTE CARLO O9 98000 |
Noreen Henig | officer: Chief Medical Officer | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
John Franklin Fowler | director, officer: CEO | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Christopher J. Kirk | director, officer: President and CSO | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Marc Belsky | officer: Chief Financial Officer | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Vassiliki Economides | officer: SVP, Strategy & External Aff. | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Elizabeth Garner | director | 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Gp, Llc | 10 percent owner | 100 HIGH STREET, SUITE 1105, BOSTON DC 02110 |
Bay City Capital Llc | 10 percent owner | 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111 |
From GuruFocus
By Business Wire • 07-07-2023
By Business Wire Business Wire • 11-09-2022
By Business Wire Business Wire • 07-11-2022
By Business Wire Business Wire • 11-03-2022
By Business Wire Business Wire • 11-10-2022
By Business Wire Business Wire • 09-01-2022
By Business Wire Business Wire • 02-06-2023
By Business Wire Business Wire • 01-13-2023
By Business Wire Business Wire • 08-11-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.